Collegium Pharmaceutical, Inc. (COLL)
22.02
+0.18
(+0.82%)
USD |
NASDAQ |
Oct 02, 16:00
22.05
+0.03
(+0.14%)
After-Hours: 20:00
Collegium Pharmaceutical Gross Profit Margin (Quarterly) : 55.18% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 55.18% |
| March 31, 2026 | 60.59% |
| December 31, 2025 | 62.49% |
| September 30, 2025 | 61.70% |
| June 30, 2025 | 57.65% |
| March 31, 2025 | 54.75% |
| December 31, 2024 | 54.02% |
| September 30, 2024 | 60.76% |
| June 30, 2024 | 62.51% |
| March 31, 2024 | 63.11% |
| December 31, 2023 | 63.19% |
| September 30, 2023 | 58.75% |
| June 30, 2023 | 54.47% |
| March 31, 2023 | 53.47% |
| December 31, 2022 | 42.10% |
| September 30, 2022 | 46.33% |
| June 30, 2022 | 42.38% |
| March 31, 2022 | 57.90% |
| December 31, 2021 | -4.87% |
| September 30, 2021 | 58.49% |
| Date | Value |
|---|---|
| June 30, 2021 | 60.57% |
| March 31, 2021 | 63.38% |
| December 31, 2020 | 58.07% |
| September 30, 2020 | 60.87% |
| June 30, 2020 | 61.96% |
| March 31, 2020 | 50.96% |
| December 31, 2019 | 33.85% |
| September 30, 2019 | 35.90% |
| June 30, 2019 | 35.16% |
| March 31, 2019 | 34.02% |
| December 31, 2018 | 59.52% |
| September 30, 2018 | 34.44% |
| June 30, 2018 | 35.89% |
| March 31, 2018 | 32.38% |
| December 31, 2017 | 89.86% |
| September 30, 2017 | 95.37% |
| June 30, 2017 | 83.79% |
| March 31, 2017 | 82.92% |
| December 31, 2016 | 63.24% |
| September 30, 2016 | 25.98% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Innoviva, Inc. | 73.64% |
| Zevra Therapeutics, Inc. | 95.36% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 16.72% |
| Return on Assets | 2.76% |
| Return on Invested Capital | 3.74% |
| Profit Margin (Quarterly) | -7.53% |
| Operating Margin (Quarterly) | 2.94% |
| Return on Net Operating Assets | 3.70% |